Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Rhea-AI Summary

Ayala Pharmaceuticals (Nasdaq: AYLA) will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. This clinical-stage oncology company specializes in developing small molecule therapeutics aimed at rare and aggressive cancers, particularly in genetically defined populations. The company's presentation is scheduled for March 15, 2022, from 10:40 AM to 11:10 AM EDT. Additionally, Ayala will engage in one-on-one investor meetings at the event. More details can be found on their website.

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the 32^nd Annual Oppenheimer Healthcare Conference, taking place on March 15-17, 2022. The company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

32nd Annual Oppenheimer Healthcare Conference
Format:	Virtual Presentation
Date:	Tuesday, March 15, 2022
Time:	10:40 AM – 11:10 AM EDT

A webcast of the presentation will be available on the “Events and Presentations” section of the Ayala Pharmaceuticals website.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com  

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com 

FAQ

When will Ayala Pharmaceuticals present at the Oppenheimer Healthcare Conference?

Ayala Pharmaceuticals will present on March 15, 2022, at the Oppenheimer Healthcare Conference.

What is the focus of Ayala Pharmaceuticals' research?

Ayala Pharmaceuticals focuses on developing small molecule therapeutics for rare and aggressive cancers.

What time is Ayala Pharmaceuticals' presentation at the conference?

The presentation by Ayala Pharmaceuticals will take place from 10:40 AM to 11:10 AM EDT on March 15, 2022.

Where can I find more information about Ayala Pharmaceuticals?

More information about Ayala Pharmaceuticals can be found on their official website at ayalapharma.com.

Is Ayala Pharmaceuticals involved in any clinical trials?

Yes, Ayala Pharmaceuticals is conducting clinical trials for their product candidates, AL101 and AL102.